Filtered By:
Condition: Pancreatitis
This page shows you your search results in order of date.
Order by Relevance | Date
Total 170 results found since Jan 2013.
Hypertriglyceridemia-Induced Pseudo –High Anion Gap Metabolic Acidosis Manifesting as Ischemic Stroke
Hypertriglyceridemia is a metabolic disorder characterized by elevated levels of triglycerides in the bloodstream.1 The underlying causes are multifactorial and range from metabolic syndrome and genetic predisposition to lifestyle choices.1 The management of hypertriglyceridemia usually involves a combination of lifestyle modifications, control of low-density lipoprotein and high-density lipoprotein levels, and pharmacotherapy when necessary.1 The clinical presentation is predominantly asymptomatic; however, some patients present with abdominal pain, nausea, vomiting, and pancreatitis.
Source: Mayo Clinic Proceedings - September 1, 2023 Category: Internal Medicine Authors: Abdul R. Akkawi, Mason Fawcett, Abhiram Challa, Timothy Nguyen, Jennifer Jackson, Richard Muraga Tags: Letter to the editor Source Type: research
Endovascular Management of Life-Threatening Hemoptysis in Primary Lung Cancer: A Retrospective Study
ConclusionEndovascular treatment for primary lung cancer-related hemoptysis is effective but not uneventful.
Source: CardioVascular and Interventional Radiology - June 13, 2023 Category: Radiology Source Type: research
What to Know About High Triglycerides
Discussions about heart health often center around blood pressure and cholesterol, with factors like poor sleep, smoking, family history of heart disease, and chronic stress thrown in. However, there’s one variable that doesn’t get covered as often, even though it can be an important indicator of cardiovascular risk: triglycerides.
“We don’t really talk about triglycerides very much, especially compared to cholesterol, but they’re actually an essential part of understanding heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health in New York. “For some...
Source: TIME: Health - May 23, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news
SNHG11 ：A New Budding Star in Tumors and Inflammatory Diseases
CONCLUSION: LncRNA SNHG11 can serve as an early diagnostic biomarker, therapeutic target, and prognostic indicator in various diseases, particularly tumors. SNHG11 plays a crucial role in the occurrence and development of tumors and inflammatory diseases through various mechanisms, which has significant implications for clinical diagnosis and treatment.PMID:37165588 | DOI:10.2174/1389557523666230509122402
Source: Mini Reviews in Medicinal Chemistry - May 11, 2023 Category: Chemistry Authors: Yinxin Wu Source Type: research
Hypertriglyceridemia may contribute to stroke and pancreatitis: A case report and review of the literature
Front Endocrinol (Lausanne). 2022 Dec 1;13:960343. doi: 10.3389/fendo.2022.960343. eCollection 2022.NO ABSTRACTPMID:36531479 | PMC:PMC9751361 | DOI:10.3389/fendo.2022.960343
Source: Atherosclerosis - December 19, 2022 Category: Cardiology Authors: Mingyu Zhang Taoyuan Yin Feng Xia Suhong Xia Wangdong Zhou Yu Zhang Xu Han Kai Zhao Lina Feng Ruonan Dong Dean Tian Yan Yu Jiazhi Liao Source Type: research
Advancements of Prussian blue-based nanoplatforms in biomedical fields: Progress and perspectives
J Control Release. 2022 Oct 7:S0168-3659(22)00677-0. doi: 10.1016/j.jconrel.2022.10.007. Online ahead of print.ABSTRACTPrussian blue (PB) nanoparticles possess excellent physicochemical properties, including imaging features, robust photothermal conversion ability, catalytic activity, surface modifiability, effective drug loading, good stability, biocompatibility and biodegradability. With the advancement of nanotechnology, diverse PB-based nanoplatforms have been developed for biomedical applications. This review systematically summarized recent studies on PB-based nanoplatforms in the treatment of tumor (photothermal the...
Source: Atherosclerosis - October 10, 2022 Category: Cardiology Authors: Yanhui Wang Zonghao Liang Ziyang Liang Wenfeng Lv Min Chen Yi Zhao Source Type: research
Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis
Conclusion: Semaglutide should be considered when GLP-1 RAs are indicated for T2DM patients.
Source: Frontiers in Pharmacology - December 24, 2021 Category: Drugs & Pharmacology Source Type: research
Ischemic Stroke in a Child after a Probable Scorpion Sting
We report a 2-year-old Venezuelan boy presenting with acute pancreatitis and pulmonary edema without an identifiable cause 48 hours after his initial symptoms. We administered antivenom therapy when an undetected scorpion sting was suspected. Despite some initial clinical improvement with respect to his acute pancreatitis, pulmonary edema, and coagulation abnormalities, our patient experienced an ischemic stroke. Fortunately, our patient did demonstrate some neurological improvement. Although acute pancreatitis and pulmonary edema are known end-organ damage manifestations of the sting of Tityus in the Americas, our particu...
Source: Am J Trop Med Hyg - November 29, 2021 Category: Infectious Diseases Authors: Laura Naranjo Fernando Carrillo-Villase ñor Gina D'Suze Carlos Sevcik Nathan Gundacker Amy Rao Carlos Franco-Paredes Jos é Antonio Suárez Source Type: research
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
CONCLUSIONS: Findings from both standard and network meta-analyses of moderate- to high-certainty evidence suggest that GLP-1RA and SGLT2i are likely to reduce the risk of CVD mortality and all-cause mortality in people with established CVD; high-certainty evidence demonstrates that treatment with SGLT2i reduce the risk of hospitalisation for HF, while moderate-certainty evidence likely supports the use of GLP-1RA to reduce fatal and non-fatal stroke. Future studies conducted in the non-diabetic CVD population will reveal the mechanisms behind how these agents improve clinical outcomes irrespective of their glucose-lowerin...
Source: Cochrane Database of Systematic Reviews - October 25, 2021 Category: General Medicine Authors: Takayoshi Kanie Atsushi Mizuno Yoshimitsu Takaoka Takahiro Suzuki Daisuke Yoneoka Yuri Nishikawa Wilson Wai San Tam Jakub Morze Andrzej Rynkiewicz Yiqiao Xin Olivia Wu Rui Providencia Joey Sw Kwong Source Type: research
